Patients with advanced chronic kidney disease (CKD) suffer from a wide range of symptoms influencing their quality of life, morbidity and mortality rates. In order to provide better insight into the association between kidney function decline and symptom development in elderly patients with advanced CKD (eGFR ≤20mL/min/1.73m2) a prospective European Quality study on treatment in […]
Therapeutic plasma exchange (TPE) is performed in a wide range of hematologic, neurologic, rheumatologic, renal and conditions related to organ transplantation. However, indications and outcomes are still mostly based on adult studies and evidence-based data are still lacking for the pediatric population which can also benefit from this procedure in specific circumstances. Research by Guntulu […]
Lumasiran is an investigational RNAi therapeutic that inhibits oxalate production by targeting hydroxyacid oxidase 1, which depletes glycolate oxidase. The latest results from the phase 3 ILLUMINATE-A trial suggest that lumasiran effectively reduces urinary oxalate excretion at 6 months in patients with type 1 primary hyperoxaluria. Furthermore, it was well tolerated and was not associated […]
IgA nephropathy is a leading causes of chronic renal disease and end stage renal disease (ESRD). The risk of progression to ESRD is associated with the level of proteinuria, thus underlining the importance of adequate proteinuria control. A prospective, single-center, randomized controlled study followed patients with IgA nephropathy and moderate proteinuria of 1.0–3.0 g/24 h receiving valsartan, […]
Peritonitis is still a major concern for peritoneal dialysis (PD) patients and caregivers. The latest Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) reports the results from an observational prospective cohort investigation of 7,051 adult PD patients from seven countries. The crude peritonitis rate was 0.28 episodes per patient-year, ranging from 0.26 in the United […]
Uremic pruritus remains an important issue in haemodiaysis patients. It has a high prevalence and is often associated with poor sleep quality, psychological disturbances, risk of infections and even death. Several interventions have been attempted with limited success thus far. Difelikefalin, a peripherally restricted and selective agonist of kappa opioid receptors might be a promising […]
The new GlomCon/ERA-EDTA roundtable discussion is scheduled today, January 14,2020 at 4 pm CET, 5 pm GMT and 8 am PST. Dr Anastasiia Rind will discuss on “microRNA: From Physiology to Disease – Applications in Nephrology” with Dr Kate Stevens and Dr Laura Denby.
The 2017 Annual Report of the ERA-EDTA Registry reveals that only a small fraction of patients accepted for renal replacement therapy are able to start this treatment with the best available therapy, which is transplantation, and that the number of people who are in need of renal replacement therapy is rising. This poses a major […]
ERA-EDTA Operative Headquarters
Via XXIV Maggio 38
43123 Parma – Italy
Phone: +39 0521 989078
Fax: +39 0521 959242
E-mail: secretariat@era-edta.org
ERA-EDTA Registered Office
c/o PKF Littlejohn, 15 Westferry Circus, Canary Wharf
London E14 4HD – United Kingdom